NEW YORK, March 11, 2026  — Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, announced today that Chief Medical Officer Janet Choi, MD, will present new fertility research during the first annual Health and Human Services (HHS) National Conference on Women’s Health, March 11-13, 2026, in Washington, DC. The event will bring together leaders across the industry to explore breakthroughs in research, prevention, diagnosis, and treatment of health conditions that affect women across the lifespan.

Progyny’s participation in the conference represents the company’s role in contributing to and helping shape the national conversation on advancing women’s health. As a recognized leader in fertility, family building, and women’s health benefits, Progyny has spent the past decade partnering with employers, health plans, and clinical leaders to elevate the standard of care, improve outcomes for women and families, and advance innovation. The company has one of the largest data sets on fertility in the U.S., providing a unique ability to gather insights that can improve health outcomes.

The fertility research being presented, co-authored by Alan Copperman, MD, Managing Director and CEO of RMA of New York, assessed how integrated education and clinician-guided decision-making influence treatment selection, timing, clinical outcomes, and cost of care. Key findings include:

• Early cycle awareness can support informed decision-making: Nearly half of women who received early cycle-aware education did not  pursue fertility treatment.

• Personalized fertility care can help patients reach pregnancy more efficiently, limiting the emotional and physical toll: In this member population – where benefit design did not mandate step-protocol requirements – time to achieve a successful pregnancy in days was up to 42% shorter.
• Age remains an important factor in fertility treatment success: In this analysis, only approximately 8% of IUI (intrauterine insemination) cycles were successful among patients age 35 and over, reinforcing the importance of timely evaluation and individualized care planning.
• Individualized treatment decisions may help optimize birth outcomes and cost: Treatment pathways should consider the risk of multiples which can increase the likelihood of neonatal intensive care needs and associated costs.

“Fertility care is highly personal and time-sensitive, and treatment decisions should reflect each patient’s clinical circumstances. These findings underscore the value of personalized, clinician-guided care in helping patients make informed decisions about their family building journey,” said Janet Choi, MD, Chief Medical Officer, Progyny. “The selection of Progyny’s fertility research for presentation at this national forum highlights the relevance of evaluating how fertility care pathways affect patient experience and outcomes.”

To learn more about Progyny’s fertility research, please visit:  progyny.com/superior-outcomes.

About Progyny 

Progyny (Nasdaq: PGNY) is a global leader in women’s health and family building solutions, trusted by the nation’s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians. 

Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women’s health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. 

Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes’ Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com. 

For Further Information, Please Contact: 

Media: 
Alexis Ford 
media@progyny.com 

Investors: 
James Hart 
investors@progyny.com 

The post Progyny to Participate in Inaugural HHS Women’s Health Conference appeared first on Progyny.

The ‘Press Play on Pause’ campaign features voices from leading employers including Synchrony, Danone and more, as well as some of today’s biggest women’s health advocates like Female Quotient Founder and CEO Shelley Zalis, actress Kellee Stewart, Mama Glow Founder Latham Thomas, and Gennev Founder and CEO Jill Angelo. Each woman’s story and call to action will be shared across Progyny’s LinkedIn and Instagram accounts throughout October.

In addition to the social campaign, Progyny has curated a list of resources to support women in the workplace and educational materials for someone currently in peri/menopause.   

• For consultants and employers considering menopause benefits – For those looking to better support employees during peri/menopause, we encourage you to utilize our Comprehensive Menopause Benefit Checklist. Adding comprehensive menopause benefits can be life-changing for employees experiencing the symptoms of this transition.

• For those experiencing menopause – We got you! If you are a Progyny member, your dedicated Progyny Care Advocate is available to answer any questions you might have regarding resources and treatment. If you are not a Progyny member, we have free educational resources to help guide you through this transition. Feel free to visit our Instagram for stories from patients, explore resources, and be a part of the community. Lastly, feel free to email info@progyny.com should you have any questions about making the case for menopause benefits at your company.

As we continue to push the conversation around menopause forward, Progyny remains committed to ensuring women have the resources and support they need. By raising awareness, encouraging open dialogue, and providing meaningful benefits, we hope to empower millions of women to embrace this stage of life with confidence and clarity. Together, through the ‘Press Play on Pause’ campaign, we can break the silence and build a future where menopause is no longer a taboo topic but a natural and supported part of the workplace and everyday life.

^[1] National Menopause Foundation 

The post Progyny ‘Presses Play on ‘Pause’ in Honor of World Menopause Awareness Month appeared first on Progyny.

This prestigious honor is awarded to those enterprises that contribute most significantly to economic growth, and is presented by The Financial Times and Statista Inc., the world-leading statistics portal and industry ranking provider. Millions of companies in North and South America were examined, with only the top 500 firms awarded. 

With compounded annual revenue growth of 80+ percent over the last 7 years, as well as having signed 105 new clients, added 1.2 million lives covered, and sustained our near 100% client retention rate in the last year alone, we believe this recognition is well founded.   

Complete results can be viewed here.   

Most importantly, this award underscores the increasing demand among employers both to offer fertility and family building benefits and to put their trust in us as the leading solution. With that, thank you to all of our client and provider partners who make our exceptional growth possible and thank you to our Progyny employees – your continued dedication to our mission of making dreams of parenthood come true is what keeps this company consistently in the top ranks of awards such as this.

– Mark Livingston, CFO

The post Progyny Named on The Financial Times’ List of Americas’ Fastest Growing Companies for Fourth Consecutive Year appeared first on Progyny.

The annual list highlights top, New York-based health care leaders who have moved the needle in their organizations, shown commitment to their life-changing work, and brought numerous contributions to their industry. At Progyny, Dr. Copperman serves as the cornerstone of our medical expertise, presenting the most current insights and information around assisted reproductive technology and guiding the future offerings at the company. His approach to reproductive medicine combines individualized, patient-focused care with data-driven medical decisions and the latest advancements in reproductive science, making him an indispensable resource to both our team and Progyny members.  

The award issue, which was released today (August 22, 2022), details each awardee’s accomplishments. Dr. Copperman’s excerpt reads: 

Dr. Alan Copperman 
CEO, Reproductive Medicine Associates of New York; Medical director, Progyny
Copperman is division director and clinical professor of obstetrics, gynecology and reproductive science at the Icahn School of Medicine at Mount Sinai. He also is a reproductive endocrinologist and infertility specialist. He has co-written hundreds of scientific abstracts on in vitro fertilization, egg freezing, ovum donation and genetics. Recently he conducted a landmark study on Covid-19 vaccine safety for fertility patients. Copperman, who is medical director at Progyny, a fertility benefits management company, has led lectures, webinars and panel discussions on genomics; precision medicine; the use of artificial intelligence; and personalized, patient-focused medicine. He serves as fellowship director at the Icahn School of Medicine. Copperman has developed interdisciplinary programs with the Mount Sinai Center for Transgender Medicine and Surgery. 

For more information about Crain’s New York Business 2022 Notable Health Care Leaders, visit their website, www.crainsnewyork.com.  

For more information about Progyny, visit www.progyny.com. 

The post Progyny Congratulates Its Medical Director Dr. Alan Copperman for Being Recognized as One of Crain’s New York Business 2022 Notable Health Care Leaders  appeared first on Progyny.

The final list recognizes 250 companies that are agile enough to maneuver but also big enough to have a broad impact. Together, these companies employ 35 million people, about one of four U.S. workers. All 250 have a successful track record with leadership teams that spur solid performance, create value, penetrate markets, engage with customers, and more.  

To be considered for the list, each company had to fill out an application answering questions about its performance, executive team, and leadership. Applicants were then analyzed via an algorithm that identified the very best companies according to their leadership teams’ superlative accomplishments in four key areas: performance and value creation; market penetration and customer engagement; talent; and leadership team.  

“This inaugural list of companies represents the remarkable midsized companies, both public and private, often founder led, that are at the vanguard of reinventing American business,” says Scott Omelianuk, editor-in-chief of Inc. magazine. “With their leadership, all business will benefit from an exciting, competitive future full of possibilities.”  

“It is an honor for Progyny to be named to Inc.’s Best-Led Companies List,” said David Schlanger, CEO of Progyny. “This recognition is a testament to how the company has thrived this past year, especially during a global pandemic, and how we have continued to collaborate as a team.” 

Progyny’s benefits solution empowers patients with education and guidance from a dedicated Patient Care Advocate (PCA), provides access to a premier network of fertility specialists and the most appropriate treatments and approved technologies to give doctors and patients the best chance of success. Our solution also reduces healthcare costs for the nation’s leading employers and drives optimal clinical outcomes. We envision a world where anyone who wants to have a child can do so. 

For more information on Progyny, visit www.progyny.com.  

To see the complete list, visit www.inc.com/best-led-companies.  

The post Progyny Named to Inc.’s First-Annual Best-Led Companies List appeared first on Progyny.

Progyny, a leading fertility benefits management company, is honored to rank #20 on The Financial Times inaugural list of The Americas’ Fastest Growing Companies. This prestigious award is presented by The Financial Times and Statista Inc., the world-leading statistics portal and industry ranking provider.

The list is comprised of the enterprises that contribute most heavily to economic growth. Millions of companies in North and South America were examined, with only the top 500 firms awarded.

Progyny’s fertility benefits solution empowers patients with education and guidance from a dedicated Patient Care Advocate (PCA), provides access to a premier network of fertility specialists using the latest science and technologies, reduces healthcare costs for the nation’s leading employers, and drives optimal clinical outcomes. We envision a world where anyone who wants to have a child can do so.

Complete results can be viewed here.

The post Progyny Ranks #20 on The Financial Times’ List for The Americas’ Fastest Growing Companies for 2020 appeared first on Progyny.

The interactive, digital program, designed specifically for Progyny and its members, uses science-based activities and exercises from leading clinical psychologist, Dr. Georgia Witkin. Dr. Witkin is an assistant professor in both the Department of Obstetrics, Gynecology and Reproductive Science and the Department of Psychiatry at Mount Sinai Medical Center and is Head of Patient Development Services at Progyny. Dr. Witkin has focused her career on the impact infertility has on emotional wellbeing, and the design of clinically-proven methods to help members through various stages of infertility and the related treatments.

Resources on-demand
By participating in Happify Health exercises, Progyny members can regain a sense of control, develop effective coping strategies for stress, anxiety and negativity and, ultimately, manage their emotions in a way that supports their fertility objectives (with a goal of shortening the path to pregnancy).

“Infertility is a disease that has a significant impact on emotional health, including self-esteem,” said David Schlanger, CEO of Progyny. “Women and men dealing with infertility can have elevated levels of stress, anxiety and depression which, in turn, can impact physical health. We are proud to partner with Happify, the pioneer of evidence-based digital emotional health solutions, to bring this exciting new emotional support tool to our members.”

Progyny members can access the proprietary track, “How to Survive the Emotional Roller Coaster of Infertility,” through the Progyny member portal or Happify’s iOS and Android apps. Progyny members also have access to 24 additional Happify Health tracks designed to improve feelings of happiness and promote resilience and mindfulness. The activities and games in each interactive track are based on more than 20 years of research in the fields of positive psychology, mindfulness and cognitive behavior therapy (CBT).

Science-based emotional wellbeing resources, delivered online
Happify Health’s digital guided exercises for individuals experiencing symptoms of anxiety and depression have been designed to improve overall emotional wellbeing. A 2016 study published in The Journal of Medical Internet Research¹ explored the relationships among Happify Health usage, language and outcomes. The study found that Happify users, predominantly aged 25-54 who used various Happify activities to address negative thoughts through the Happify Health platform on a regular basis were able to improve their positivity.

“At Happify Health, we believe that the systems and channels to deliver mental and emotional support resources can be vastly improved,” said Ofer Leidner, president and co-founder of Happify Health. “The team at Progyny saw an opportunity for us to combine clinically-proven resources from a leading fertility psychologist with Happify Health’s activities designed to reduce stress, depressive symptoms and anxiety. But most importantly, by offering this to members, Progyny is opening up access to effective emotional wellbeing resources to members at a time when they need it most.”

Online emotional wellbeing resources can be as effective as traditional resources and allow people to engage with the resources at any time, on any device. By changing the system and channels used to deliver assistance, Happify Health is helping increase access and reduce the stigma around asking for help – making it easy to engage and interact at a crucial time.

About Progyny
Progyny is a leading fertility benefits management company that combines clinical and emotional guidance, science, technology and data to provide comprehensive value-based fertility solutions for self-insured employers. Progyny’s benefit plans are designed to improve outcomes, shorten time to pregnancy and reduce total fertility-related costs. Progyny is privately held and is headquartered in New York, N.Y. Please visit www.progyny.com.

About Happify Health
Happify Health, a leader in mental health and wellness technology breaks down barriers to achieving better emotional health by creating an engaging, stigma-free environment that allows individuals to access online resources with any device – at the place and time when it matters most. Our clinical, evidence-based activities and interventions are designed to be effective, and our digital, gamification approach helps users create positive change in their lives by developing skills to reduce stress and build resilience. Happify Health uses scientific research from positive psychology, CBT and mindfulness and combines it with leading-edge technology to impact everyday lives. For more information go to www.happifyhealth.com.

¹ Seeing the “Big” Picture: Big Data Methods for Exploring Relationships Between Usage, Language, and Outcome in Internet Intervention Data. http://www.jmir.org/2016/8/e241/

###

The post Progyny and Happify Health Give People Dealing with Infertility New Digital Emotional Support Tools appeared first on Progyny.